Näytetään tulokset 1 - 10 / 11
tulosta / sivu
Mitä julkaisutietoja palvelu sisältää?
Julkaisun nimi
Tekijät
Julkaisukanava
Vuosi

Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study

Vertaisarvioitu
DOI
10.1530/eje.1.02331
Majuri, Anna; Santaniemi, Merja; Rautio, Katriina; Kunnari, Anne; Vartiainen, Johanna; Ruokonen, Aim...
European journal of endocrinology2007

Systematic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPAR agonist

Vertaisarvioitu
Badeau RM; Honka MJ; Lautamäki R; Stewart M; Kangas AJ; Soininen P; Ala-Korpela M; Nuutila P
Annals of Medicine (helsinki)2013

Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPAR? agonist

Vertaisarvioitu
DOI
10.3109/07853890.2013.853369
Badeau Robert M, Honka Miikka-Juhani, Lautamäki Riikka, Stewart Murray, Kangas Antti J, Soininen Pas...
Annals of Medicine2013

Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPAR gamma agonist

Vertaisarvioitu
DOI
10.3109/07853890.2013.853369
Robert M. Badeau, Miikka-Juhani Honka , Riikka Lautam\303\244ki, Murray Stewart , Antti J. Kangas, P...
Annals of medicine2014

Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPAR gamma agonist

Vertaisarvioitu
DOI
10.3109/07853890.2013.853369
Badeau, Robert M; Honka, Miikka-Juhani; Lautamäki, Riikka; Stewart, Murray; Kangas, Antti J; Soinine...
Annals of medicine2014

Pioglitazone and bladder cancer risk : a multipopulation pooled, cumulative exposure analysis

Vertaisarvioitu
DOI
10.1007/s00125-014-3456-9
Levin, Daniel; Buchan, Iain E; Bowker, Samantha L; Minhas-Sandhu, Jasjeet K; Zafari, Zafar; Marra, C...
Diabetologia2015

Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation

Vertaisarvioitu
DOI
10.1042/BSR20140115
Tikka, Anna;Soronen, Jarkko;Laurila, Pirkka-Pekka;Metso, Jari;Ehnholm, Christian;Jauhiainen, Matti
BIOSCIENCE REPORTS2015

Effects of different insulin sensitisers in the management of polycystic ovary syndrome: A systematic review and meta‐analysis

Vertaisarvioitu
Avoin saatavuus
DOI
10.1111/cen.14983
Melin, Johanna M.; Forslund, Maria; Alesi, Simon J.; Piltonen, Terhi; Romualdi, Daniela; Spritzer, P...
Clinical endocrinology2023

Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension

Vertaisarvioitu
Avoin saatavuus
DOI
10.1111/j.1742-1241.2012.02975.x
Gomis, R.; Owens, D. R.; Taskinen, Marja-Riitta; Del Prato, S.; Patel, S.; Pivovarova, A.; Schlosser...
International journal of clinical practice2012

Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable

Vertaisarvioitu
Avoin saatavuus
DOI
10.1093/eurheartj/ehy677
Cosentino, Francesco; Ceriello, Antonio; Baeres, Florian; Fioretto, Paola; Garber, Alan; Stough, Wen...
European heart journal2019

Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study

Vertaisarvioitu
DOI
10.1530/eje.1.02331
2007

Systematic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPAR agonist

Vertaisarvioitu
2013

Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPAR? agonist

Vertaisarvioitu
DOI
10.3109/07853890.2013.853369
2013

Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPAR gamma agonist

Vertaisarvioitu
DOI
10.3109/07853890.2013.853369
2014

Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPAR gamma agonist

Vertaisarvioitu
DOI
10.3109/07853890.2013.853369
2014

Pioglitazone and bladder cancer risk : a multipopulation pooled, cumulative exposure analysis

Vertaisarvioitu
DOI
10.1007/s00125-014-3456-9
2015

Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation

Vertaisarvioitu
DOI
10.1042/BSR20140115
2015

Effects of different insulin sensitisers in the management of polycystic ovary syndrome: A systematic review and meta‐analysis

Vertaisarvioitu
Avoin saatavuus
DOI
10.1111/cen.14983
2023

Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension

Vertaisarvioitu
Avoin saatavuus
DOI
10.1111/j.1742-1241.2012.02975.x
2012

Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable

Vertaisarvioitu
Avoin saatavuus
DOI
10.1093/eurheartj/ehy677
2019